Next Article in Journal
All You Can Feed: Some Comments on Production of Mouse Diets Used in Biomedical Research with Special Emphasis on Non-Alcoholic Fatty Liver Disease Research
Previous Article in Journal
Efficacy and Safety of Resveratrol in Type 1 Diabetes Patients: A Two-Month Preliminary Exploratory Trial
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Alexandre-Gouabau et al. “Comprehensive Preterm Breast Milk Metabotype Associated with Optimal Infant Early Growth Pattern”, Nutrients, 2019, 11, 528

by
Marie-Cécile Alexandre-Gouabau
1,*,
Thomas Moyon
1,
Agnès David-Sochard
1,
François Fenaille
2,
Sophie Cholet
2,
Anne-Lise Royer
3,
Yann Guitton
3,
Hélène Billard
1,
Dominique Darmaun
1,4,
Jean-Christophe Rozé
1,4 and
Clair-Yves Boquien
1,5
1
INRA, UMR1280, Physiopathologie des Adaptations Nutritionnelles, Institut des maladies de l’appareil digestif (IMAD), Centre de Recherche en Nutrition Humaine Ouest (CRNH), F-44093 Nantes, France
2
Service de Pharmacologie et d’Immunoanalyse, Laboratoire d’Etude du Métabolisme des Médicaments, CEA, INRA, Université Paris Saclay, MetaboHUB, F-91191 Gif-sur-Yvette, France
3
LUNAM Université, ONIRIS, Laboratoire d’Etude des Résidus et Contaminants dans les Aliments (LABERCA), USC INRA 1329, F-44307 Nantes, France
4
CHU, Centre Hospitalo-Universitaire Hôtel-Dieu, F-44093 Nantes, France
5
EMBA, European Milk Bank Association, I-20126 Milano, Italy
*
Author to whom correspondence should be addressed.
Submission received: 12 December 2019 / Accepted: 17 December 2019 / Published: 7 January 2020
The authors wish to make a correction to Section 2.7 and Table 4 in the published version of their paper [1].
A reverse digit error was found when reporting the monosaccharide compositions of Human Milk Oligosaccharides (HMOs) in Table 4 and, in particular, in the order of hexose (Hex), N-acetylhexosamine (HexNac), fucose (Fuc), and N-acetylneuraminic acid (NeuAc) numbers in the first 12 HMOs. A corrected version of Table 4 is shown below.
One edit to the sentence in the paragraph of 2.7. Lipidomic, Metabolomic, and Glycomic Data Treatment and Metabolites Annotation is needed: “When it was not possible to clearly determine HMO structures, HMOs were named according to their monosaccharide compositions and denoted as hexose (Hex), fucose Fuc), N-acetylhexosamine (HexNac), and N-acetylneuraminicacid (NeuAc) numbers”. This sentence should now read: “When it was not possible to clearly determine HMOs structures, HMOs were named according to their monosaccharide compositions and denoted as hexose (Hex), N-acetylhexosamine (HexNAc), fucose (Fuc), and N-acetylneuraminic acid (NeuAc) numbers”.
This change does not affect anything in the overall results of the selection of HMO biomarkers of infant early growth.
The authors would like to apologize for any inconvenience caused to readers by these changes.

Conflicts of Interest

No funder/sponsor had any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; the preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.

References

  1. Alexandre-Gouabau, M.C.; Moyon, T.; David-Sochard, A.; Fenaille, F.; Cholet, S.; Royer, A.L.; Guitton, Y.; Billard, H.; Darmaun, D.; Rozé, J.C.; et al. Comprehensive preterm breast milk metabotype associated with optimal infant early growth pattern. Nutrients 2019, 11, 528. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Table 4. Major Human Milk Oligosaccharides HMOs detected in breast milk glycome and provided to preterm infants with “faster” or “slower” growth during the W2 to W4 lactation period.
Table 4. Major Human Milk Oligosaccharides HMOs detected in breast milk glycome and provided to preterm infants with “faster” or “slower” growth during the W2 to W4 lactation period.
HMOs CompositionMedian (25% and 75% Percentile) from W2 to W4 (Secretors and Non-Secretor Mothers)Mann–Whitney p-value (FDR-Corrected MW q-Value in Exposant)VIP–PLS-DA (C1–C2)MLR p-Value
(FDR-Corrected MLR q-Value in Exposant)
mzRTHexHexNAcFucNeuAc“Slower” Growth (n = 38)“Faster” Growth (n = 29)Secretors and Non-SecretorsSecretors OnlySecretors and Non-SecretorsSecretors OnlySecretors and Non-SecretorsSecretors Only
Fucosylated 61.46 (50.28–65.13)62.82 (60.20–65.19)0.1847 t0.1370 0.73
Sialylated 8.47 (6.97–9.40)7.45 (6.70–9.11)0.25450.2773 0.37
Fucosylated./Sialylated 1.95 (1.50–2.32)1.63 (1.33–2.30)0.0973 t0.1422 0.35
Neutral 28.30 (26.78–38.23)26.87 (25.92–29.57)0.0352 *0.6966 0.95
Mono Fucosylated 28.49 (19.06–34.74)36.95 (31.83–39.21)0.00200.0669 0.19
Di Fucosylated 26.64 (23.83–28.53)23.12 (19.14–26.77)0.00260.0054 * 0.10
Tri Fucosylated 3.52 (2.96–4.00)2.85 (2.63–3.26)0.00610.0883 0.43
Tetra Fucosylated 3.20 (2.54–4.07)2.94 (1.77–3.83)0.15200.0243 * 0.004 *
LNFPI≠856.3280 10.2311011.99 (0.36–18.65)19.86 (15.00–23.69)0.0003 **0.0045 *1.221.260.630.03 *
pLNH≠1075.40231842000.26 (0.14–0.35)0.38 (0.26–0.54)0.0014 **0.0013 *1.441.750.500.10 *
2′-FL≠491.1958 8.5201011.22 (0.10–13.87)12.58 (10.29–15.09)0.0882 t0.94331.101.080.630.22 *
6′-SL636.23339.620012.50 (2.30–3.06)2.47 (1.81–3.05]0.32190.94330.650.290.260.31 *
LNnH≠1075.402315.142000.82 (0.32–1.44)0.95 (0.58–2.31)0.0689 t0.81161.251.220.670.52 t
LNT/LNnT≠710.2701 10.9310022.52 (20.29–35.65)22.46 (20.04–25.21)0.1991 t0.25911.000.810.480.62 t
LSTc/b1001.3655 18.431012.59 (2.00–3.57)2.63 (2.25–3.41)0.70120.14220.890.870.780.65 t
LNDFH I1002.3859 5.731204.26 (0.44–6.25)5.10 (0.51–6.96)0.39860.89030.550.740.220.50 t
3′ FL491.1958 1.820100.03 (0.00–0.08)0.00 (0.00–0.03)0.0133 *0.16970.940.700.120.09 *
3′ SL636.2333 18.920010.15 (0.13–0.21)0.14 (0.11–0.18)0.1555 t0.94330.460.480.260.16 *
LNDFH ≠1002.3859 9.631200.26 (0.14-0.36)0.36 (0.27-0.45)0.0020 **0.10501.121.050.430.04 *
LNDFHx1002.3859 6.831200.26 (0.11–1.11)0.14 (0.07–0.24)0.0293 *0.0726 t0.971.040.150.06 *
4230c≠1513.5760 13.542300.11 (0.00–0.18)0.07 (0.04–0.14)0.54050.0002 **1.901.550.0062 *0.07 *
4210d≠1221.4602 17.442100.18 (0.00–0.39)0.47 (0.27–1.31)0.0005 **0.0142 *1.691.660.100.04 *
4220e≠1367.5181 1342201.59 (0.37–2.43)1.75 (1.35–2.77)0.1799 t0.61281.281.760.860.78 t
4230b≠1513.576 8.242300.65 (0.00–1.49)0.61 (0.06–1.20)0.79670.0893 t1.381.330.0095 *0.09 *
3000≠507.1907 6.430000.26 (0.19–0.31)0.16 (0.12–0.23)<0.0001 ***0.0022 *2.060.900.530.22 *
5300 (2+)720.7709 18.153000.15 (0.10–0.23)0.16 (0.14–0.32)0.0771 t0.63051.411.390.720.37 *
6420c (2+)≠1049.394918.164200.44 (0.09–0.64)0.50 (0.32–0.72)0.1893 t0.52201.110.670.300.76 t
6430d (2+)≠1122.4238 16.864300.14 (0.00–0.26)0.15 (0.10–0.24)0.2102 t0.26631.181.000.340.87 t
5310c1586.5924 1853100.29 (0.22–0.38)0.38 (0.25–0.46)0.0428 *0.40940.901.020.950.16 *
2110a694.2752 3.621100.01 (0.00–0.27)0.24 (0.00–0.51)0.0811 t0.67720.901.490.480.60 t
4240b≠1659.6339 13.942400.04 (0.00–0.11)0.04 (0.00–0.08)0.96540.0457 *1.290.680.0007 **0.05 *
2020a≠637.253711.120200.49 (0.04–0.61)0.55 (0.45–0.66)0.0840 t0.97001.101.230.720.20 *
5310b1586.59241753100.24 (0.13–0.31)0.16 (0.09–0.27)0.1091 t0.0420 *0.930.970.840.40 *
4220a684.2627 7.742200.20 (0.14–0.29)0.11 (0.07–0.25)0.0216 *0.0911 t0.490.520.100.82 t
4220b≠1367.5181 8.842200.31 (0.09–1.78)0.23 (0.07–0.33)0.0895 t0.33521.020.990.150.14 *
4210b≠1221.4602 12.642107.19 (5.03–8.90)3.75 (2.37–6.33)<0.0001 ***0.0003 **1.051.840.300.07 *
5330b1878.7082 13.953300.23 (0.00–0.39)0.29 (0.00–0.38)0.37490.41060.961.100.050.26 *
5320a1732.6503 12.953200.27 (0.13–0.70)0.13 (0.05–0.22)0.0004 **0.0045 *1.061.370.470.16 *
Relative HMO abundances (%) were calculated by dividing absolute HMO peak area by each sample’s total HMO peak areas. Values are medians (25% and 75% percentiles) from relative HMOs abundances from week 2 to week 4 of lactation period. P-values for comparison between “faster” and “slower” growth groups were derived by using Mann–Whitney U test. Variables were considered significantly modified between the two groups of infants’ growth when their multiple comparisons adjusted p-values (e.g., q-value after False Discovery Rate (FDR)) was <0.05. *: FDR-corrected MW q-value < 0.05; **: FDR-corrected MW q-value < 0.01; ***: FDR-corrected MW q-value < 0.001; t: FDR-corrected MW q-value < 0.1. Multiple Linear Regression (MLR) for infant weight Z-score (p-value) was also combined with FDR and predictive ability for infant weight growth were considered reliable when MLR q-value was <0.05. *: FDR-corrected MLR q-value < 0.05; t: FDR-corrected MLR q-value < 0.1. ≠: variables of importance for Partial Least Square-Discriminant Analysis (PLS-DA) model (VIP > 1.0). LNDFH, Lacto-N-difucosyl-hexaose; LNT, lacto-N-tetraose; pLNH, p-Lacto-N-Hexaose; LNFP, lacto-N-fucopentaose; LNnT, lacto-N-neotetraose; LNT, lactoN-tetraose; LST, sialyl-lacto-N-tetraose; 2′-FL, 2′-fucosyllactose; 3-FL, 3-fucosyllactose; 3′-SL, 3′-sialyllactose; Hex, hexose; HexNac, N-acetylhexosamine; Fuc, fucose and NeuAc, N-acetylneuraminic acid. Fucosylation was further investigated to determine difference in abundance of mono, di, tri, and tetrafucosylation (based on the number of fucose residues).

Share and Cite

MDPI and ACS Style

Alexandre-Gouabau, M.-C.; Moyon, T.; David-Sochard, A.; Fenaille, F.; Cholet, S.; Royer, A.-L.; Guitton, Y.; Billard, H.; Darmaun, D.; Rozé, J.-C.; et al. Correction: Alexandre-Gouabau et al. “Comprehensive Preterm Breast Milk Metabotype Associated with Optimal Infant Early Growth Pattern”, Nutrients, 2019, 11, 528. Nutrients 2020, 12, 162. https://0-doi-org.brum.beds.ac.uk/10.3390/nu12010162

AMA Style

Alexandre-Gouabau M-C, Moyon T, David-Sochard A, Fenaille F, Cholet S, Royer A-L, Guitton Y, Billard H, Darmaun D, Rozé J-C, et al. Correction: Alexandre-Gouabau et al. “Comprehensive Preterm Breast Milk Metabotype Associated with Optimal Infant Early Growth Pattern”, Nutrients, 2019, 11, 528. Nutrients. 2020; 12(1):162. https://0-doi-org.brum.beds.ac.uk/10.3390/nu12010162

Chicago/Turabian Style

Alexandre-Gouabau, Marie-Cécile, Thomas Moyon, Agnès David-Sochard, François Fenaille, Sophie Cholet, Anne-Lise Royer, Yann Guitton, Hélène Billard, Dominique Darmaun, Jean-Christophe Rozé, and et al. 2020. "Correction: Alexandre-Gouabau et al. “Comprehensive Preterm Breast Milk Metabotype Associated with Optimal Infant Early Growth Pattern”, Nutrients, 2019, 11, 528" Nutrients 12, no. 1: 162. https://0-doi-org.brum.beds.ac.uk/10.3390/nu12010162

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop